Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842772 | 0.88 | ALDH1A1 (0.41) | MAPK1CNR2GPBAR1ALDH1A1STAT3 | |
| SCHEMBL842507 | 0.80 | CACNA1H (0.41) | MAPK1CYP3A4ALDH1A1MAPTTSHR | |
| SCHEMBL9493247 | 0.80 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL2817700 | 0.80 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL9493435 | 0.80 | CYP11B2 (0.43) | MAPK1CYP11B2ALDH1A1TSHR | |
| SCHEMBL10494022 | 0.79 | KMT2A (0.48) | MAPK1CYP11B2POLB | |
| SCHEMBL843562 | 0.77 | KMT2A (0.43) | CYP11B2KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL2818685 | 0.76 | KDM4C (0.44) | MAPK1TDO2IDO1CYP11B2KDM4E | |
| SCHEMBL9673472 | 0.76 | MAPK1 (0.40) | MAPK1IDO1CYP11B2POLB | |
| SCHEMBL2817853 | 0.74 | SLC6A2 (0.41) | MAPK1TDO2IDO1CYP11B2RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-8143278-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-27 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093711-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-15 | — | — | US | disclosed |
| EP-2121652-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076860-A1 | 4-IMIDAZOLYL-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS ALDOSTERONE/11-BETA-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093711-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP11B2 | NOTUM 148/4885MAPK1 1399/4885BRD4 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.